Dr. Osborne obtained his BS with honors from Penn State University, his MD magna cum laude from Jefferson Medical College, and his PhD in cardiovascular physiology from Thomas Jefferson University. After graduation, he continued his post- doctoral studies at Harvard Medical School and Brigham and Women’s Hospital in Boston, Massachusetts, where he completed his Internship, Residency, and Research Residency in Internal Medicine and a Fellowship in Cardiovascular Disease. While at Harvard, Dr. Osborne published many articles on atherosclerosis, vascular biology, and molecular genetics. During his cardiology fellowship, he spent two years in the Department of Genetics at Harvard Medical School doing his postdoc in molecular genetics and positional clone genes for both dilated cardiomyopathy and hypertrophic cardiomyopathy.  His clinical training focused on non-invasive techniques, and he is the only physician board certified in Cardiology and Internal Medicine, Lipidology, Clinical Hypertension, Cardiac CT Angiography, Echocardiography, and Nuclear Cardiology. His clinical interests include preventive cardiology, cardiometabolic disease, diabetes, hypertension, congestive heart failure, cholesterol disorders, cardiovascular genetics, cardiac AI-enhanced CT angiography, and identifying and implementing novel technologies for in-home and travel related clinical services.

He is the Director of Cardiovascular CT at the Carrollton Regional Medical Center, which just installed the nation’s first Atlas 960 640-Slice Cardiac CT Scanner. He is the consulting physician overseeing clinical medicine and innovation for Market Dynamics (now IQVIA In-home Clinical Services) for over 14 years, which focuses on life sciences consultancy services and has a nationwide US presence to support in-office and in-home testing, medication initiation, and monitoring services.

His most current project is ClearCardio™️, which is the nation’s leading preventive cardiology organization that intends to eliminate cardiovascular disease by combining leading-edge cardiovascular imaging with AI-based imaging analyses. These tools are able to detect, quantify, and monitor cardiovascular disease and plaque to a degree never before possible. Utilizing state-of-the-art imaging with his knowledge of proven tools of plaque treatment, cardiovascular disease, the leading cause of mortality and morbidity in the US (and globally), could be largely eliminated in the next few years.

He is also a consultant to a variety of innovative biotech companies that supply devices, AI, and ground-breaking technologies to provide cutting-edge medical care at home or anywhere in the world.